Compare Eli Lilly And Co (LLY) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Eli Lilly And Co trades at $1,173.02 (market cap $1.04T), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.64 (market cap $7.77B). The key difference: Eli Lilly And Co is far larger — about 133.8× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| LLY | PDBC | |
|---|---|---|
Market Cap | $1.04T | $7.77B |
Volume | 3,064,878 | 6,100,303 |
Sector | Health | — |
52-Week High | $1.28K | $20.10 |
52-Week Low | $799.57 | $13.16 |
Typical Hold Time | 93 Days | 56 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
PDBC (Invesco Optimum Yield Diversified Commodity Strategy ETF) trades at $19.68, up 1.39% with strong bullish momentum. The ETF has delivered exceptional performance, rising 45.66% year-to-date driven by energy and agricultural gains amid geopolitical turmoil. Technical indicators show bullish moving averages but neutral oscillators, with RSI at 72.89 suggesting potential overbought conditions. Recent institutional activity shows significant position increases despite a 215% surge in short interest.
The outlook remains positive given strong commodity trends and defensive positioning appeal, though elevated short interest and geopolitical risks warrant caution. Commodity exposure provides inflation hedge benefits, but price volatility and concentrated sector risks require careful monitoring for investors seeking diversified commodity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
